Ferritin light chain pseudogene 14 (FTLP14)

Ferritin light chain pseudogene 14 (FTLP14) is a processed or retrotransposed pseudogene annotated in the human genome (ENSEMBL ID: ENSG00000260459, Entrez ID: 100462794) and located at chromosome 16q22.1[1]. It is a member of the ferritin gene family but does not code for a functional protein, nor does it serve as a receptor, enzyme, transporter, or other classical therapeutic target class. Like many pseudogenes, it is believed to be non-functional, and there is no evidence it is transcribed or has a protein product. It is distinct from the functional ferritin light chain gene (FTL), which encodes an essential iron storage protein. There are no currently known implications of FTLP14 in disease, no drugs targeting it, and no recognized use as a biomarker or therapeutic target. The use of FTLP14 as a pharmacological or physiological target is incorrect[1]. Context and supporting details: - FTLP14 is specifically described as a pseudogene, lacking the capacity to encode a functional protein[1]. - It differs from other ferritin-related pseudogenes that are sometimes transcribed (such as FTH1P3, which encodes a long non-coding RNA), but no evidence exists for FTLP14 being transcriptionally active in any context[1][2]. - Ferritin light chain (FTL) itself is coded by another gene, while FTLP14 is one of multiple pseudogenes scattered throughout the genome[1][3][4]. - Pseudogenes like FTLP14 are generally not considered drug targets because they do not produce a functional protein product and usually lack biological function[1][2]. Summary judgment: - FTLP14 is not a therapeutic, biological, or pharmacological target. Its inclusion as such would be incorrect. If "ferritin light chain pseudogene 14" is being treated as a drug target or biomarker, that is a mistake based on the current biological and medical knowledge.

Other names

FTLP14ferritin light chain pseudogene 14